| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-20 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.380 | -0.530 | -0.1500 | ||||
| REV | 0 |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Elevation Oncology (NASDAQ: ELEV) through any online brokerage.
Other companies in Elevation Oncology’s space includes: Vincerx Pharma (NASDAQ:VINC), Syros Pharmaceuticals (NASDAQ:SYRS), Alzamend Neuro (NASDAQ:ALZN), AVEO Pharmaceuticals (NASDAQ:AVEO) and Orchard Therapeutics (NASDAQ:ORTX).
The latest price target for Elevation Oncology (NASDAQ: ELEV) was reported by HC Wainwright & Co. on December 23, 2021. The analyst firm set a price target for 12.00 expecting ELEV to rise to within 12 months (a possible 111.64% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Elevation Oncology (NASDAQ: ELEV) is $5.67 last updated Fri Jan 21 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Elevation Oncology.
Elevation Oncology’s $Q4 earnings are confirmed for after-market on February 20, 2022.
There is no upcoming split for Elevation Oncology.
Elevation Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.